Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study
(2022) In Acta Neurologica Scandinavica 145(6). p.743-752- Abstract
Background: Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives: First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. Materials and methods: The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn... (More)
Background: Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives: First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. Materials and methods: The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016. Results: In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs. Conclusion: Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.
(Less)
- author
- M. Norlin, Jenny
; Hjalte, Frida
; Kruse, Christopher
; Dodel, Richard
; Rosqvist, Kristina
LU
and Odin, Per
LU
- organization
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cost of illness, late-stage Parkinson's disease, quality of life, Sweden
- in
- Acta Neurologica Scandinavica
- volume
- 145
- issue
- 6
- pages
- 743 - 752
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:35312034
- scopus:85126774584
- ISSN
- 0001-6314
- DOI
- 10.1111/ane.13611
- language
- English
- LU publication?
- yes
- id
- 73350b2c-2ba9-41e4-9b57-599ecb717015
- date added to LUP
- 2022-04-20 15:31:26
- date last changed
- 2025-01-28 07:51:23
@article{73350b2c-2ba9-41e4-9b57-599ecb717015, abstract = {{<p>Background: Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. Objectives: First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. Materials and methods: The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016. Results: In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs. Conclusion: Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients’ HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.</p>}}, author = {{M. Norlin, Jenny and Hjalte, Frida and Kruse, Christopher and Dodel, Richard and Rosqvist, Kristina and Odin, Per}}, issn = {{0001-6314}}, keywords = {{cost of illness; late-stage Parkinson's disease; quality of life; Sweden}}, language = {{eng}}, number = {{6}}, pages = {{743--752}}, publisher = {{Wiley-Blackwell}}, series = {{Acta Neurologica Scandinavica}}, title = {{Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study}}, url = {{http://dx.doi.org/10.1111/ane.13611}}, doi = {{10.1111/ane.13611}}, volume = {{145}}, year = {{2022}}, }